Abstract
Diclofenac-sodium, a non-steroidal anti-inflammatory drug presents a new strategy in the treatment of urolithiasis by virtue of its effects on calcium excretion1. However, its effect on inhibitory potential of urine in stone formers has not been studied. In the present study we have clinically evaluated the effect of diclofenac sodium upon 2 urinary inhibitors of calcium oxalate crystallization.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Reference
C Collette, L Aquiore, L Mommier, and A Mimrau, Renal Physiol. 6: 68 (1982).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sharma, S., Vaidyanathan, S., Thind, S.K., Nath, R. (1994). Therapeutic Role of Diclofenac-Sodium in Management of Hypocitraturia and Hypopyrophosphaturia in Idiopathic Stone Formers. In: Ryall, R., Bais, R., Marshall, V.R., Rofe, A.M., Smith, L.H., Walker, V.R. (eds) Urolithiasis 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2556-1_266
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2556-1_266
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6091-9
Online ISBN: 978-1-4615-2556-1
eBook Packages: Springer Book Archive